Introduction {#Sec1}
============

End-stage liver failure (ESLF) is a life-threatening condition of patients with collapsing liver function, caused by massive death of liver cells. The clinical syndrome comprises bleeding risks or thrombosis, disturbed acid--base homeostasis, systemic inflammatory response, hemodynamic instability, hepatic encephalopathy (HE) with the risk of increased intracranial pressure (ICP) and multi-organ failure.

Different types of ESLF are distinguished: acute liver failure (ALF), when ESLF occurs in a person with a previous healthy liver and Acute on Chronic Liver Failure (ACLF) in a patient with an already compromised liver, mostly cirrhosis.

The incidence of ACLF in the Western World is about 70.000 patients per year and for ALF about 8000 \[[@CR1]\]. At present, standard medical therapy consists of treating the cause of deterioration, maintaining hemodynamic stability, fluid-, acid/base- and electrolyte balance, supplying fresh frozen plasma in case of bleeding, preventing increasing ICP and, optionally hemodialysis \[[@CR2]\].

Nevertheless, mortality rates are high, up to 80%, depending on the cause of ESLF and the number of failing organs \[[@CR3]\]. The heterogeneity between the pathophysiology of the ESLF patients severely complicates the standardization of an effective treatment \[[@CR4]\]. At present liver transplantation (LTX) is the only lifesaving therapy. In the EU one-year survival rates after liver LTX are 74% for ALF patients and 85% for ACLF patients (European Liver Transplant Registry 1988--2015), however, the low supply of donor livers limits the impact of LTX \[[@CR5]\].

There is an unmet need for improving standard medical therapy to such extent that the waiting time for LTX can be prolonged and the patient enters surgery in a better condition or, ideally, that the native liver regenerates.

Different liver support strategies have been developed, including non-cell based and cell-based artificial liver supportive systems (ALSS), cell transplantation and high volume plasma exchange.

Here, we summarize the state-of-the-art of liver support strategies for ESLF and analyze remaining problems and possible solutions.

Non-cell-based ALSS {#Sec2}
===================

All the non-cell-based ALSS rely on extracorporeal albumin purification, either by albumin dialysis, fractionated plasma separation, or replacement of albumin and/or adsorption techniques. These therapies aim to remove albumin-bound toxins which accumulate in the plasma. A limited number of studies has been performed on pigs with ALF caused by complete liver ischemia or overdose of acetaminophen (APAP). No ACLF models were tested. These experiments show that non-cell based albumin purification devices have the potential to improve biochemical parameters and ICP, while ADVOS and DIALIVE also improve survival time (Table [1](#Tab1){ref-type="table"}).Table 1Large-animal studies with Non-Cell Based Artificial Liver Support devicesSupplier/expert centerYearDeviceCharacteristicsStudy designOutcomes \[reference\]Gambro/University Tromsø, Norway2006M-MARSModified MARS, Albumin dialysis without hemofiltrationCS in liver ischemia pigs; (*n* = 8/group)Delayed ICP rise \[[@CR53]\]Gambro/University Tromsø, Norway2007MARSAlbumin dialysis and charcoal adsorptionCS in liver ischemia pigs; (*n* = 8/group)Improvement of biochemistry \[[@CR54]\]Fresenius/Charles University, Prague, Czech Republic2009PrometheusFractionated plasma separation and adsorptionCS in liver ischemia pigs; (*n* = 14 treatment vs *n* = 8 control group)Delayed ICP and bilirubin rise \[[@CR55]\]Hepa Wash GmbH/ Klinikum rechts der Isar, Technische Universität, München, Germany2013ADVOSAlbumin dialysis with albumin regeneration through biochemical and physical modulationCS in liver ischemia pigs; (*n* = 6 treatment vs *n* = 5 control group)Improvement of multi-organ failure and delayed rise of ammonia and protein-bound toxins increased short-term survival \[[@CR56]\]Fresenius/Charles University, Prague, Czech Republic2014PrometheusFractionated plasma separation and adsorptionCS in liver ischemia pigs; (*n* = 14 treatment vs *n* = 7 control group)Delayed ICP rise, but no effect on hemodynamics \[[@CR57]\]UCL London, UK2015DIALIVEAlbumin exchange and endotoxin removalCS in pigs with APAP overdose; (*n* = 9 treatment vs *n* = 7 control group)Survival benefit \[[@CR58]\]

Table [2](#Tab2){ref-type="table"} shows the results of clinical studies of non-cell based ALSS: two randomized clinical trials (RCTs), one controlled clinical trial (CCT) and one uncontrolled trial, as well as seven retrospective studies comparing two or more groups. Most of the studied treatments positively affected biochemical parameters and secondary endpoints, like HE, but whether a significant effect on the primary endpoint, i.e. improved survival rates, has been established, remains controversial \[[@CR6]\]. A meta-analysis in 2013 of eight RCTs showed that non-cell based ALSS reduced mortality in ACLF patients (*p* \< 0.018), but not in ALF patients \[[@CR7]\]. In contrast, a meta-analysis in 2015 \[[@CR8]\], comparing MARS treatment with standard medical therapy, showed significant effect on survival in 93 ALF patients (*p* = 0.04), and no survival effect in 453 ACLF patients. Subsequent clinical studies continued to produce contradictory results with albumin dialysis systems. Gerth et al. \[[@CR9]\], in a retrospective study of 101 ACLF patients, confirmed improved short-term mortality in ACLF by MARS, but the same group failed to improve 28-day mortality in ALF \[[@CR10]\]. These apparent contradictory results need further clarification. It is most likely that only specific subgroups of ESLF patients, i.e. those with less severe liver failure, may profit from non-cell based ALSS. A combination with plasma exchange (PE) seems to improve the impact of non-cell based ALSS therapy; controlled studies on non-cell based ALSS showed predominantly improved survival in those combination therapies (2 out of 2 studies \[[@CR11], [@CR12]\]), while stand-alone non-cell based ALSS therapies predominantly failed to provide any survival benefit (negative studies: \[[@CR10], [@CR13]--[@CR15]\]) with the exception of two positive studies \[[@CR9], [@CR16]\].Table 2Clinical studies with non-cell based artificial liver support systemsSupplier/expert centerYearDeviceCharacteristicsStudy designOutcomes \[reference\]Zhejiang University, Hangzhou, China2005ALSSPlasma exchange, charcoal adsorption, bilirubin adsorptionCCT in ACLF patients (*n* = 338 treatment *vsn* = 312 controls)Improved 30-day survival and biochemistry \[[@CR11]\]Gambro-Baxter/Jena University, Germany2009SPAD and/or MARSSPAD: Single --Pass Albumin DialysisMARS: Albumin dialysis and charcoal adsorptionRetrospective comparison in ALF/ACLF patients with MARS (*n* = 33), SPAD (*n* = 12) or MARS & SPAD combined (*n* = 12)Biochemical improvement from baseline \[[@CR59]\]Fresenius/University Duisburg-Essen, Germany2012PrometheusFractionated plasma separation and adsorptionRCT in ACLF patients (*n* = 77 treatment *vsn* = 68 controls)Biochemical improvement, no survival benefit \[[@CR13]\]Gambro-Baxter/Hospital General, Madrid, Spain2013MARSAlbumin dialysis and charcoal adsorptionRCT in ACLF patients (RELIEF) (*n* = 95 treatment *vs* 94 controls)No survival benefit \[[@CR14]\]Gambro-Baxter/University of Muenster, Germany2017MARSAlbumin dialysis and charcoal adsorptionStudy 1. Retrospective comparison of ACLF patients (*n* = 47 treatment *vsn* = 54 controls)Study 2CCT in ALF/graft dysfunction patients (*n* = 32 treatment *vsn* = 41 controls)Study 1. Biochemical and clinical improvement and improved short-term survival \[[@CR9]\]Study 2No survival benefit \[[@CR10]\]Hepa Wash GmbH/Klinikum rechts der Isar, Technische Universität, München, Germany2017ADVOSAlbumin dialysis with albumin regeneration through biochemical and physical modulationUncontrolled study in ACLF patients (*n* = 9)Biochemical improvement from baseline \[[@CR60]\]Gambro-Baxter/University Maryland, Baltimore, USA2017MARSAlbumin dialysis and charcoal adsorptionRetrospective, uncontrolled study in ALF patients (*n* = 27)Improvement of grade of HE \[[@CR61]\]Nephrology Dept, Dali University, Chuxiong, China2018PD or PEPeritoneal Dialysis or plasma exchangeRetrospective comparison in ALF and ACLF patients, PD (*n* = 22), PE (*n* = 28) *vs* controls (*n* = 12)PD improved survival and biochemistry \[[@CR16]\]Capital Medical University, Beijing, China2018DPMAS and PEDouble plasma molecular adsorption and plasma exchangeRetrospective comparison of HBV-ACLF patients, DPMAS + PE (*n* = 54), *vs* PE (*n* = 77)Improved bilirubin and 28-day survival rate \[[@CR12]\]Fresenius/University of Lodz, Poland2019PrometheusSPADCoupled plasma filtration and adsorption or SPADRetrospective comparison ESLF patients (*n* = 48 treatment *vsn* = 53 controls)No difference in 3-month mortality \[[@CR15]\]Graduate School of Medicine, Chiba, Japan2019CHDFContinuous hemodiafiltration and plasma exchangeRetrospective comparison of fulminant hepatitis patients (*n* = 47) *vs* controls (*n* = 45)Improvement of grade of HE \[[@CR62]\]

In summary, different albumin purification devices unequivocally reduce elevated plasma bilirubin, and haemodialysis reduces plasma ammonia levels. Consequently, HE grade might be improved. This reduction of HE, may, in combination with removal of albumin-bound toxins ameliorate ESLF. According to the meta-analyses \[[@CR7], [@CR8]\] in a minority of cases, non-cell based ALSS improved survival time, but it is unlikely that stand-alone non-cell based ALSS will prevent liver transplantation, as normalization of coagulation, electrolyte balance, body homeostasis and cardiovascular stability requires a more complete restoration of failing liver function. Nevertheless, new systems, like DIALIVE and ADVOS, which show short-term survival benefit in animals with ALF, are under investigation, but we have to wait for their clinical benefit on survival.

Cell-based ALSS {#Sec3}
===============

Bioartificial liver (BAL) devices {#Sec4}
---------------------------------

A BAL is an extracorporeal device containing liver cells to be connected temporarily to the patient's circulation compensating the failing detoxification, synthetic and homeostatic function of the diseased liver. An optimal BAL device promotes liver cell differentiation by allowing medium perfusion, 3-dimensional growth and supplying oxygen and contains sufficient liver cell mass (at least 20% of the native liver, approximating 15.10^9^ or 150 g hepatocytes) that provides stable support of multiple liver-specific functions \[[@CR17]\]. Therefore, a BAL has more potency to be effective than non-cell ALSS. Besides highly functional, the ideal biocomponent of BALs should be of human origin, safe and cost effective.

Many BAL-devices have been studied in experimental models of large animals with ALF (Table [3](#Tab3){ref-type="table"}); only few have reached clinical application (Table [4](#Tab4){ref-type="table"}).Table 3BAL devices in preclinical development in large animal modelsSupplier/expert centerYearDeviceCharacteristicsStudy designOutcomes \[references\]Vital Therapies/Baylor College of Medicine, USA1994ELADHollow fiber bioreactor with C3A cells (200 g)Uncontrolled study in three dogs with total hepatectomy and five dogs with overdose APAPSafety shown \[[@CR63]\]HepArt Medical Devices/University of Amsterdam, the Netherlands1999/2002AMC-BALPerfused scaffold bioreactor with primary porcine hepatocytes (14 billion in first study and 10.7 billion in second study) in 3DTwo CS's in liver ischemia pigs (c: *n* = 10, eB: *n* = 5, cB: *n* = 8) and anhepatic pigs (c, eB & cB: *n* = 5)Improved survival time and biochemistry \[[@CR64], [@CR65]\]Los Angeles School of Medicine, USA2001HepatAssistCryopreserved porcine hepatocytes (10 billion) and charcoal adsorptionCS in liver ischemia pigs (c, eB & cB: *n* = 5)Delayed ICP rise, improved survival time \[[@CR66]\]Hong Kong Ltd Co/PLA General Hospital, Beijing, China2001TECA-1 BALSSHollow fiber, freshly isolated porcine hepatocytes (10 billion)CS in dogs partial hepatectomy (cB: *n* = 10, eB: *n* = 4)Improved survival time and biochemistry \[[@CR67]\]Jichi Medical School, Japan2005Circulatory flow bioreactorCytochrome P450 3A4 and Glutamine Synthetase overexpressing HepG2 cells (100 million)CS in dogs with liver ischemia and diazepam overdose (c: *n* = 3, eB: *n* = 7, cB: *n* = 8)Improved survival time \[[@CR68]\]National Research Institute Tokyo, Japan2006Circulatory flow bioreactorGlutamine Synthetase overexpressing HepG2 cells (3.5--4.1 billion)CS in liver ischemia pigs (c: *n* = 8, eB: *n* = 9, cB: *n* = 8)Improved survival time and biochemistry, delayed ICP rise \[[@CR69]\]Thomas E. Starzl TX Institute Pittsburgh, USA2007Excorp Medical BLSSHollow fiber, 70 g primary porcine hepatocytes, blood perfusionCS in dogs with D-GALN overdose (c: *n* = 6, cB: *n* = 9, no eB)Reduced metabolic acidosis \[[@CR70]\]Southern Medical University, Guangzhou, China2014HBALSSHuman cell bank liver cells (HL-7702) (4 billion) in microcarriers in perfusion bioreactorCS in cynomolgus monkeys with D-GALN overdose (c: *n* = 5, cB: *n* = 10, no Eb)Improved survival time and biochemistry \[[@CR71]\]Mayo Clinics, USA2015SR-BALPorcine hepatocyte spheroids (59--228 g) plus plasma filtrationCS in pigs with D-GALN overdose (c, eB & cB: *n* = 6)Improved survival and biochemistry, delayed ICP rise \[[@CR72]\]University of Compiègne, France2015SuppliverFluidized bed bioreactor with detoxification columns, alginate encapsulated C3A cells (15% liver mass)Uncontrolled study in two healthy sheepSafety shown \[[@CR73]\]University Shanghai, China2016hiHep-BALRadial flow bioreactor with 65 flat layers (2D);hiHep cells (transdifferentiated human fibroblasts) (3 billion)CS in eight mini-pigs with D-GALN overdose (c: *n* = 6, eB: *n* = 6, cB: *n* = 8)Prolonged survival and improved biochemistry \[[@CR74]\]Hangzhou University, China2016FBBALFluidized bed, alginate encapsulated primary porcine hepatocytes (5 billion)CS in pigs with D-GALN overdose (c, eB & cB: *n* = 7)Change in serum metabolome and prolonged survival time \[[@CR75]\]University College London, UK2017UCLBALFluidized bed-based bioreactor with alginate beads of human HepG2 cells (70 billion)CS in liver ischemia pigs (eB: *n* = 16, cB: *n* = 13)Biochemical improvement and delayed ICP rise \[[@CR34]\]Samsung Medical Center, Korea2017LifeLiverAlginate encapsulated primary porcine hepatocytes (20 billion)CS in liver Ischemia pigs(c, eB & cB: *n* = 5)Prolonged survival time, improved biochemistry and delayed ICP rise \[[@CR76]\]Mayo Clinics, USA/ Sichuan University, China2018SRBALPorcine hepatocyte-human umbilical vein endothelial cell organoids (25.6 ± 4.1 billion cells) plus plasma filtrationCS in monkeys with α--amanitin and lipopolysaccharide intoxication (c, eB, cB: *n* = 6)Improved survival time and biochemistry \[[@CR77]\]Mayo Clinics USA2019SRBALPrimary porcine hepatocytes spheroids (200 g) plus plasma filtrationCS in post-hepatectomy pigs (c, eB, cB: *n* = 6)Improved survival time, neuroprotective benefit, improved biochemistry and accelerated liver regeneration \[[@CR78]\]Table 4Clinically applied BAL devicesSupplier/expert centerYearDeviceCharacteristicsStudy designOutcomes \[references\]Beijing and Nanjing Universities, China2001TECA-HALSS/HBALHollow fiber hybrid BAL, charcoal adsorption and primary porcine hepatocytes (10--20 billion)Uncontrolled study, six ALF and three ACLF patientsSafety, improved grade of HE \[[@CR79]\]Thomas E. Starzl TX Institute Pittsburgh, USA2002BLSSHollow fiber, primary porcine hepatocytes (70--100 g)Uncontrolled study, one ALF patientSafety shown \[[@CR80]\]Charité, Berlin, Germany2003Cell Module BioreactorModular Extracorporeal Liver Support; primary porcine hepatocytes (1.8--4.4 billion)Uncontrolled study, eight ALF patientsSuccessfully bridged to transplantation \[[@CR23]\]Cedars Sinai Medical Center, Los Angeles, USA2004HepatAssistCryopreserved porcine hepatocytes (7 billion) and charcoal adsorptionRCT, ALF patients treated (*n* = 85 treatment *vsn* = 86 control group)No survival benefit by intent-to--treat \[[@CR18]\]HepArt Medical devices B.V./University of Amsterdam, the Netherlands2005AMC-BALPerfused scaffold; primary porcine hepatocytes (7--15 billion) in 3DUncontrolled study, twelve ALF patients11/12 successfully bridged to transplantation and 1/12 spontaneous recovery \[[@CR81]\]Vital Therapies/University of Minnesota, Minneapolis, USA2018ELADHollow fiber, 440 g C3A cellsRCT, severe alcoholic hepatitis patients (*n* = 96 treatment *vsn* = 107 control group)No survival benefit by intent-to-treat \[[@CR20]\]

Preclinical BAL studies {#Sec5}
-----------------------

The applied large animal models relied on ALF caused by complete liver ischemia, total hepatectomy, overdose of drugs, such as D-galactosamine (D-GALN) and APAP, or intoxication with α-amanitin and lipopolysaccharide. Most controlled studies (CSs) included three groups; control with no connection to the system (c), empty-BAL (eB) and cell-filled-BAL (cB). Studies that did not include the eB group are less informative, as dilution of plasma or blood by pre-filling the extracorporeal circuit may lead to attenuation of ESLF. Most CSs in animals (13 out of 15) showed a beneficial effect on survival and biochemical markers. One study even reported that BAL treatment accelerated liver regeneration (56). So far, BAL systems have not been studied in animal models of ACLF.

Clinical BAL studies {#Sec6}
--------------------

Four different BAL systems based on freshly isolated porcine liver cells (BLSS, MELS, AMC-BAL and TECA-BALSS/HBAL) were tested in phase I/IIa studies and one, the HepatAssist, with cryopreserved porcine liver cells, in an RCT. All studies showed the safety of the system. However, the RCT with the HepatAssist device could not establish survival benefit in the whole patient population, analysed by intention to treat. Unexplained was an increased survival in the subpopulation of fulminant/subfulminant hepatic failure patients \[[@CR18]\]. In the uncontrolled study of the AMC-BAL plasma levels of total bilirubin and ammonia decreased by 35 and 45%, respectively, and was associated with improved neurological state and stabilization of hemodynamics \[[@CR19]\].

The ELAD system, based on the human liver cell line C3A, has been extensively tested in clinical trials with the largest ones being NCT01471028, an open-label RCT in 203 patients with severe alcoholic hepatitis \[[@CR20]\], and very recently VTL-308 in 151 less severe and relatively young alcoholic hepatitis patients (age \> 18 and \< 50 years, MELD (Model for End-Stage Liver Disease) score \< 30). Both RCTs showed temporary improvement of some biochemical parameters in ELAD-treated groups *vs* control groups, but no significant benefit on survival. By intent to treat analysis, ELAD did not meet its primary endpoint, overall survival (<https://vitaltherapies.com/research-clinical-trials-development/elad-rostock-9-29-18/>).

Concluding remarks clinically applied cell-based ALSS {#Sec7}
-----------------------------------------------------

Most BAL systems showed safety and efficacy in animal models of ESLF, indicating that supply of a broad spectrum of liver functions has a high potential to support ESLF patients. However, a clinical breakthrough has not yet been obtained, due to different factors. In Europe progress has been delayed due to the European moratorium on xenotransplantation \[[@CR21]\]. The major concerns around BAL applications with xenogeneic liver cells included immunological responses and risks associated with zoonotic infections. So far, transmission of porcine endogenous retroviruses to patients treated with BAL containing porcine cells has not been observed \[[@CR22], [@CR23]\]. Consequently, outside Europe researchers continue developing BALs based on porcine hepatocytes; the SR-BAL and LifeLiver systems are pre-clinically under investigation (Table [3](#Tab3){ref-type="table"}).

As an alternative for primary porcine hepatocytes, human liver cell lines have been most extensively applied as biocomponent for BALs. Their human origin, high reproducibility and relatively cheap propagation make them more suitable for BAL application. However, the cell lines most frequently used until now, C3A and HepG2, display a limited spectrum of liver functions and even produce lactate and ammonia, instead of eliminating it \[[@CR17]\]. This may be a reason for the disappointing outcomes of the clinical ELAD trials. Another cell source comprises original or induced stem cells, which, however, display a limited functional spectrum as well \[[@CR17], [@CR24]\]. To date, the most functional human liver cell line is the HepaRG cell line \[[@CR25]\], which further differentiates by culturing in the AMC-BAL system \[[@CR26]\]. Comparison of the transcriptomes of different proliferative sources of human liver cells showed that HepaRG cells most closely resembled primary human hepatocytes \[[@CR24], [@CR27]\]. Further improvement of existing cell systems may be achieved by (conditional) ectopic expression of limiting regulatory or structural genes and by application of cell culture systems promoting maturation, e.g. by delivering high oxygen levels, 3D configuration and perfusion \[[@CR28]\].

The development of BAL technology also faces a logistical challenge, as cells need to be provided with preservation of high functionality at the bedside. Cryopreservation of primary hepatocytes, however, may further aggravate the damage already induced by isolation \[[@CR29]\], leading to cell death or dedifferentiation. This may be the reason for the disappointing results of the HepatAssist RCT \[[@CR18]\]. Cryopreservation is substantially less damaging for proliferative cells than mature cells. In addition, liver cells rapidly deteriorate in the presence of human plasma, which limits the therapeutic window of the BAL \[[@CR30], [@CR31]\]. This negative effect can be reversed by an intermittent phase of recirculating culture medium through the bioreactor \[[@CR32]\]. Another challenge that extracorporeal BALs face is the provision of in vivo like bile secretion \[[@CR33]\]. A hybrid BAL containing a sufficient amount of well-functioning liver cells combined with integrated haemodialysis or albumin purification might be the preferred option to improve the patient's condition to create time for native liver regeneration or liver transplantation. It is evident that for clinical application, the cell- and BAL-cultures need to be produced according to Good Manufacturing Practice \[[@CR34]\].

Together, these challenges render a BAL system a complex product, and the costs of a BAL treatment will be substantial. This is actually a general problem for advanced therapies, based on cell or tissue-engineered products.

Other therapies {#Sec8}
===============

High volume plasma exchange {#Sec9}
---------------------------

By plasma exchange combined with hemoperfusion or continuous hemodiafiltration overabundant toxic substances will be removed and reduced liver-specific products will be replenished. To our knowledge, no preclinical survival studies in large animals have been performed. The first large prospective CS in HBV-associated ACLF patients (MELD score 28--29) showed higher short- and long-term survival in the treatment group (*n* = 104) *vs* the control group (*n* = 130) \[[@CR35]\].

In 2016 Larsen et al. \[[@CR36]\] showed in a RCT that high volume plasma exchange (HVPE), with 8--12 L daily volume exchange, improved survival in patients with ALF (mainly APAP overdosed) by correcting the hemodynamics and biochemistry, e.g. the ammonia levels, and by modulating the innate and adaptive immune responses to the necrotic liver \[[@CR37]\]. These two studies indicate a beneficial effect of PE or HVPE on ESLF patients. Further studies are needed to consolidate these results.

Hepatocyte or stem cell transplantation {#Sec10}
---------------------------------------

Based on several successful survival studies in large animals \[[@CR38]--[@CR40]\], cell transplantation has been studied as an alternative way of filling the treatment gap at the ICU for ESLF patients \[[@CR41]\].

Initially, hepatocytes were the cell source of choice for cell transplantation of ESLF patients. Five patients with ALF underwent intrasplenic or/and intrahepatic hepatocyte transplantation. All patients showed temporary clinical and biochemical improvement but eventually died \[[@CR42]\]. A severe complication is that for treatment of ESLF large amounts of successfully engrafting and safe hepatocytes are needed. Therefore, hepatocyte transplantation is a more promising strategy for correcting liver-based metabolic deficiencies \[[@CR43]\], requiring lower amounts of engrafted cells, and is less suitable for ESLF therapy.

Besides hepatocytes, mesenchymal stem cells (MSCs) have also been applied in cell transplantations in preclinical survival studies in large animals \[[@CR44]--[@CR49]\]. These cells do not directly support liver functions, but rather produce paracrine factors (e.g. cytokines, chemokines, and growth factors) with immunomodulatory and liver regeneration promoting effects \[[@CR50]\].

A controlled study in HBV-associated ACLF patients compared the outcomes of four groups: controls (*n* = 30): PE (*n* = 30), umbilical cord-MSC transplantation (*n* = 30) and UC-MSC + PE (*n* = 20) \[[@CR51]\]. It was concluded that MSC transplantation combined with PE treatment was safe, but could not significantly improve the short-term prognosis of HBV-ACLF patients compared to the single treatment.

An RCT on HBV-related ACLF patients showed that four weekly infusions with 100,000--1 million MSCs improved the MELD score and bilirubin levels, decreased the incidence of severe infections and increased the 24-week survival \[[@CR52]\]. These studies indicate promising results. However, further studies are needed to show the benefit of MSC transplantation in all categories of ESLF patients.

Concluding remarks {#Sec11}
==================

Interesting developments are ongoing in the field of liver support for ESLF patients. From the first non-cell-based ALSS studies we learned that detoxification modalities may temporarily yield improvement of biochemistry and grade of HE, but the supply of plasma factors, control of homeostasis, and/or modulation of the immune system are needed to effectively support ESLF patients.

BAL systems were able to improve survival in experimental animal models of ALF, but due to practical and financial problems and usage of cells with low functionality, the clinical development remains behind. Other systems as PE and MSC transplantation, both modulating the immune responses, with PE also supplying detoxification and plasma proteins, hold promise for the future as well, as survival benefit has been shown in clinical trials.

The question rises which therapy should be used in which patients and at which stage of the disease? Table [5](#Tab5){ref-type="table"} compares advantages and disadvantages of different treatment modalities for ESLF patients. Apart from providing survival benefit also other factors are relevant for decision making, including the complexity, risks and costs of the procedure, and the status of the patient. For the future, we need improved metabolic and immunologic monitoring of ESLF patients in combination with detailed measurement of the effect of the different therapies. Subsequently, therapies can be selected on the basis of informative biomarkers. This will progress the care of ESLF patients towards a more patient-tailored approach, optionally by combining different treatment modalities at different stages of the disease.Table 5Comparison of different therapies for ESLF patients

**Publisher\'s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
